
Gasporox - Executing its long-term strategy

Gasporox's results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, and after-sales services. The company is preparing to launch a new version of VialArch in June and is already securing pre-orders from the pharma and beverage sectors. The upcoming debt maturity might pressure the share, while forthcoming earnings and order announcements could boost it.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Gasporox - Executing its long-term strategy](#)